EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Phase

2/3

Condition

Atrial Fibrillation

Stroke

Chest Pain

Treatment

Empagliflozin 10 MG

Clinical Study ID

NCT06715449

IRAS: 318615

Ages > 18
All Genders

Study Summary

Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF. Whilst there has been considerable advances in AF management including improvement in ablation therapy, preventing AF remains an unmet need.

One promising avenue is a group of medications called Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, which has been studied in people with diabetes, kidney disease and weak heart muscle. These medicines were consistently found to lower the risk of developing AF. This can be promising for patients who have suffered a stroke for unclear reasons, where a significant proportion are subsequently found to have short periods of AF. Often prior to AF development, patients may have changes in the structure or function of the top chambers of their heart (the atria). This may provide a useful marker for us to understand whether SGLT2i impacts AF risk.

Aim of research study:

The aim of this study is to investigate whether the use of the drug empagliflozin, an SGLT2 inhibitor, prevents changes in the left atrium associated with future AF development. Using advanced imaging techniques and continuous rhyth monitoring we intend to study the effect of SGLT2 inhibitors on left atrial function and arrhythmia occurence.

Study design:

Patients who are undergoing an implantable loop recorder insertion, to detect AF following a stroke, will be invited for participation. Eligible consenting patients will have a baseline assessment with echocardiography, electrocardiogram and anthropometric measures. They will then be randomised to receive either the SGLT2i alongside usual stroke care for 6 months, or usual stroke care alone. All patients will be monitored remotely via their loop recorder, and will undergo repeat electrocardiogpahic, echocardiographic and anthropometric assessment at 6 months. This way, we aim to investigate whether the SGLT2 inhibitor causes changes in atrial parameters that may be associated with future AF development.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age over 18 years
Patient has had an embolic stroke of undetermined source, defined as:
Ischaemic stroke or transient ischaemic attack diagnosed clinically +supporting radiological features on CT or MRI imaging
No clinically significant extracranial or intracranial atherosclerosis found onneck imaging
No evidence of prevalent cardioembolic source of embolism - atrial dysrhythmia,cardiac thrombus, prosthetic valve, cardiac tumours, mitral stenosis, recentMI, LVEF<35%, valvular vegetations, or infective endocarditis

AND

No other specific stroke aetiology identified (pro-thrombotic states, arteritis,dissection, drug abuse)
Patient has been referred for an implantable loop recorder implant to investigatepossible atrial dysrhythmia
Ability to give written, informed consent

Exclusion

Exclusion Criteria:

Prevalent atrial fibrillation or atrial flutter
Subsequent demonstration of a cardio-emoblic source
Pre-existent indication for SGLT2i including heart failure with a reduced ejectionfraction and Type 1 or Type 2 diabetes mellitus
Contraindication to the commencement of SGLT2i including a history of, or riskfactors for diabetic ketoacidosis, such as restricted food intake or a history ofalcohol abuse
Hypersensitivity to the active substance or to any of the excipients ofempagliflozin
Presence of alternate implantable cardiac devices such as a pacemaker ordefibrillator, that would make ILR utilisation redundant
Any condition that may confound the results or interfere with participation such asdementia
An unwillingness to participate

Study Design

Empagliflozin 10 MG

2/3

November 22, 2024

March 31, 2029

Study Description

Background:

Individuals who suffer an embolic stoke of undermined source represent 17% of all ischaemic stroke patients. When they undergo continuous cardiac rhythm monitoring with a loop recorder, a large portion of the population have been noted to develop atrial fibrillation (AF). In our own centre, 48.6% of patients have found to develop AF. This is considerably more than the proportion seen in patients undergoing ILR implantation for other reasons.

What remains unclear is whether this AF may have been responsible for the initial stroke, or is a reflection of an underlying atrial cardiopathy. Moreover, it is felt that this device detected AF is an important risk factor for stroke recurrence. Recent trials have suggested that whilst anticoagulation for device detected AF reduces future stroke, this is at the expense of a significant bleeding risk. Thus far, there have been no therapies that prevent the occurrence of AF, even in groups at high risk of AF development. Obviously such a strategy would negate the risk of bleeding associated with anticoagulation use. Such a strategy would reflect a paradigm shift in AF management.

Whilst studies have tried to explore the significance of abnormal atrial function in ESUS, generally crude assessments such as P-wave terminal force in V1 and brain natriuretic peptide had been utilised. Our group deep phenotyped over 300 ESUS patients. This work highlighted an important predictive role of left atrial strain for future device detected AF.

Left atrial strain has shown great promise as a marker of atrial dysfunction. There is growing evidence that sodium glucose 2 co-transporter inhibitors, such as empagliflozin, may prevent the development of AF. There have been over a dozen metaanalyses of the safety data from the large SGLT2i outcome trials, which have consistently shown that the SGLT2i arm was associated with lower incident AF compared to the control arm.

Similar results were seen in cohort studies including in Taiwan and the Food and Drug Association's adverse events reporting system. It is this finding that prompted the interest in utilising empagliflozin as the intervention in the trial.

Study aims and objectives:

The aims of this study are to assess if:

SGLT2 inhibitors can prevent adverse changes in left atrial function in patients who are felt to have an increased chance of AF development.

A nested MRI substudy will be used to try and provide mechanistic insight into how SGLT2 inhibitors may exert an antiarrhythmic effect.

Methods:

Given that the use of SGLT2 inhibitors to prevent atrial change has not been investigated before, we aim to investigate the hypotheses with an early stage randomised controlled trial.

For this, patients undergoing implantable loop recorder insertion for AF detection following an embolic stroke of undetermined source will be invited to participate. The participants will be randomised either to usual stroke care or to the intervention arm (use of SGLT2 inhibitor in addition to usual stroke care). They will be assessed at baseline and at 6-months following initiation of the medication. Both appointments will include echocardiography, electrocardiography and anthropometric assessments such as weight and grip strength.

From each arm, 10 patients will under also undergo advanced MRI imaging including MR spectroscopy, to try and investigate possible mechanisms for any effect of the SGLT2 inhibitor.

Connect with a study center

Addenbrookes Hospital
Cambridge, Cambridgeshire CB2 0QQ
United Kingdom
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.